TGFβ released by cancer cells and other cells in the tumour microenvironment enables cancer cell invasion and dissemination, stem cell properties and therapeutic resistance as well as generating an immunosuppressive environment. The authors of this Review introduce the mechanisms underlying TGFβ signalling in tumours and their microenvironment and discuss approaches to inhibit these signalling…
Nature Reviews Clinical Oncology – ALND can be safely omitted for patients with sentinel-node macrometastases
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
Nature Reviews Clinical Oncology – T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers…
Nature Reviews Clinical Oncology – The benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer…
Nature Reviews Clinical Oncology – Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Nature Reviews Clinical Oncology – Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα…
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
Nature Reviews Clinical Oncology – A new standard of care for advanced-stage urothelial carcinoma
Nature Reviews Clinical Oncology – The composition of the gut microbiota has emerged as a tumour-extrinsic factor that modulates response to immune-checkpoint inhibitors (ICIs), although…
